Drugs / BI 1060469
last change Aug 2015 re-read 2 minutes ago

BI 1060469

Developed for
asthma
Investigated by
Boehringer Ingelheim

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02438696 May → Aug 2015 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02225626 Sep → Nov 2014 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02202512 Sep → Dec 2014 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02183545 Jul → Oct 2014 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02126865 May 2014 → Jul 2015 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT01971502 Oct 2013 → Feb 2014 Boehringer Ingelheim Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as BI 1060469 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02202512
5

NCT02225626

NCT02183545

NCT02126865

NCT02438696

NCT01971502

Route Oral “Single Ascending Oral Doses” NCT01971502